Key Highlights

  • SLS shares rose 14.07% pre-market today to $9.16 from a prior close of $8.03.
  • Phase 3 REGAL topline results are expected this month after the 80th event.
  • Cash and cash equivalents were $134.7 million as of September 30, 2026.
  • Third quarter net loss was $10.1 million, or $0.05 per share.

SELLAS Life Sciences Group (NASDAQ:SLS) shares climbed in pre-market today after the company released third quarter results and an update on its Phase 3 REGAL trial of galinpepimut-S (GPS) in acute myeloid leukemia (AML). The stock was at $9.16, up 14.07% from the prior close of $8.03, which followed a 4.63% decline in the prior session.

The company said the pre-specified 80th event has occurred in REGAL and that the final analysis is underway. It expects to report topline primary endpoint results this month, narrowing the fourth-quarter timeframe given earlier. No efficacy data from the trial has been disclosed.

SELLAS is a late-stage clinical biopharmaceutical company focused on cancer therapies. GPS, licensed from Memorial Sloan Kettering Cancer Center, targets the WT1 protein found across many tumor types. REGAL is testing it in AML patients who reached complete remission after second-line salvage therapy.

SLS009 Data and an ASH Presentation Fill the Calendar

The company is also developing SLS009 (tambiciclib), a selective CDK9 inhibitor. Forty patients have been enrolled in an 80-patient Phase 2 trial in newly diagnosed AML, with preliminary topline data expected in the fourth quarter of 2026.

Results from a completed Phase 2 study in relapsed or refractory AML will be presented at the American Society of Hematology annual meeting, held December 12 to 15 in New Orleans. The company reported a 54% overall response rate and median overall survival of 5.8 months in monocytic AML, and a 57% response rate with 8.8 months in TP53-mutated disease. It compared these with historical outcomes of about 2.5 months in those settings.

Wider Loss and Heavier Trial Spending Meet a Larger Cash Balance

The third quarter net loss widened to $10.1 million from $6.8 million a year earlier. Loss per share improved to $0.05 from $0.06 because the weighted average share count rose to 202.4 million from 108.4 million. Nine-month net loss was $28.1 million, compared with $19.2 million.

Research and development spending reached $7.0 million, up from $4.2 million, on higher manufacturing, regulatory consulting and clinical trial costs tied to preparation for a potential Biologics License Application for GPS. General and administrative expenses rose to $4.3 million from $2.9 million on stock-based compensation and professional fees.

Cash and cash equivalents stood at $134.7 million, compared with $71.8 million at the end of 2025, supported by Warrant exercises. Total liabilities were $9.3 million and stockholders' Equity was $131.8 million. Shares outstanding rose to about 203.5 million from 153.1 million, an increase of roughly 33%.

The company is pre-revenue, and its 52-week range runs from $1.39 to $15.88.

A Move Built on Timing, With the REGAL Data Still Unseen

The move rests on timing rather than data. The company has confirmed the 80th event and narrowed its REGAL readout to this month, but no efficacy numbers are public yet. The result will arrive at a company with $134.7 million in cash and about 33% more shares than at the end of 2025, with SLS009 data and the ASH presentation to follow.